Cancer-Retina Antigens in the Urine of Bladder and Prostate Cancer Patients

---

Yuri M. Shlyapnikov^1,a*, Ekaterina A. Malakhova¹, Andrey Z. Vinarov², Natalia V. Potoldykova², Vasiliy I. Vladimirov³, Evgeni Yu. Zernii⁴, Andrey A. Zamyatnin, Jr.^4,5,6, and Elena A. Shlyapnikova¹

¹Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 142290 Pushchino, Russia

²Institute for Urology and Reproductive Health, Sechenov First Moscow State Medical University, 119991 Moscow, Russia

³Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117437 Moscow, Russia

⁴Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia

⁵Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia

⁶Department of Biotechnology, Sirius University of Science and Technology, 354340 Krasnodar Region, Federal Territory Sirius, Russia

^* To whom correspondence should be addressed.

Received April 7, 2022; Revised October 2, 2022; Accepted October 10, 2022

---

It has recently been shown that combination of arrestin and recoverin can serve as an effective urinary biomarker for renal cell carcinoma with sensitivity and specificity of over 92%. In this work, we studied the possibility of detecting these antigens in the urine in other urological oncological diseases – bladder cancer (BC) and prostate cancer (PCa). Urine samples from 40 BC patients and 40 PCa patients were analyzed using an ultrasensitive microarray immunoassay with a detection limit of 0.1 pg/ml. It was shown that in BC the sensitivity of determining combination of arrestin with recoverin is 58% (AUC 0.76, 95% CI 0.66-0.86), while in PCa it is 60% (AUC 0.7, 95% CI 0.68-0.88). It has been established that in patients with bladder and prostate cancer who had a positive test, these antigens are not detected in 90% of cases after removal of the tumor. In the future, the obtained results could become the basis for developing new approaches for timely detection of relapses of such diseases and treatment control, as well as for the development of new diagnostic methods.

---

KEY WORDS: cancer-retina antigens, immunoassay, urological cancer, microarrays, magnetic particles

DOI: 10.1134/S0006297922110062

---